Literature DB >> 18312905

Anticoagulants, antiplatelets, and statins in heart failure.

Dimitrios Farmakis1, Gerasimos Filippatos, Mitja Lainscak, John T Parissis, Stefan D Anker, Dimitrios T Kremastinos.   

Abstract

The existing guidelines for the treatment of patients who have heart failure limit the administration of antiplatelet and anticoagulant agents to patients who have specific comorbidities, including coronary artery disease, atrial fibrillation, history of thromboembolic events, and left ventricular mural thrombus. Retrospective analyses of large clinical trials or smaller nonrandomized studies indicate that the use of statins may be beneficial both in ischemic and idiopathic dilated cardiomyopathy. This article outlines the current knowledge regarding the use of antiplatelet and anticoagulant agents and statins in patients who have heart failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312905     DOI: 10.1016/j.ccl.2007.10.001

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  2 in total

1.  Prevalence of conduction abnormalities in a systolic heart failure population by race, ethnicity, and gender.

Authors:  Kathy Hebert; Henry C Quevedo; Leonardo Tamariz; Andre Dias; Dylan L Steen; Rosario A Colombo; Emiliana Franco; Sholom Neistein; Lee M Arcement
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-04       Impact factor: 1.468

Review 2.  The management of atrial fibrillation in heart failure: an expert panel consensus.

Authors:  Dimitrios Farmakis; Christina Chrysohoou; Gregory Giamouzis; George Giannakoulas; Michalis Hamilos; Katerina Naka; Stylianos Tzeis; Sotirios Xydonas; Apostolos Karavidas; John Parissis
Journal:  Heart Fail Rev       Date:  2021-11       Impact factor: 4.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.